Ir directamente a la navegación principal Ir directamente a la búsqueda Ir directamente al contenido principal

Multisite assessment of NIA-AA guidelines for the neuropathologic evaluation of Alzheimer's disease

  • Thomas J. Montine
  • , Sarah E. Monsell
  • , Thomas G. Beach
  • , Eileen H. Bigio
  • , Yunqi Bu
  • , Nigel J. Cairns
  • , Matthew Frosch
  • , Jonathan Henriksen
  • , Julia Kofler
  • , Walter A. Kukull
  • , Edward B. Lee
  • , Peter T. Nelson
  • , Aimee M. Schantz
  • , Julie A. Schneider
  • , Joshua A. Sonnen
  • , John Q. Trojanowski
  • , Harry V. Vinters
  • , Xiao Hua Zhou
  • , Bradley T. Hyman

Producción científica: Article › revisión exhaustiva

97 Citas (Scopus)

Resumen

Introduction Neuropathologic assessment is the current "gold standard" for evaluating the Alzheimer's disease (AD), but there is no consensus on the methods used. Methods Fifteen unstained slides (8 brain regions) from each of the 14 cases were prepared and distributed to 10 different National Institute on Aging AD Centers for application of usual staining and evaluation following recently revised guidelines for AD neuropathologic change. Results Current practice used in the AD Centers Program achieved robustly excellent agreement for the severity score for AD neuropathologic change (average weighted κ =.88, 95% confidence interval: 0.77-0.95) and good-to-excellent agreement for the three supporting scores. Some improvement was observed with consensus evaluation but not with central staining of slides. Evaluation of glass slides and digitally prepared whole-slide images was comparable. Discussion AD neuropathologic evaluation as performed across AD Centers yields data that have high agreement with potential modifications for modest improvements.

Idioma originalEnglish
Páginas (desde-hasta)164-169
Número de páginas6
PublicaciónAlzheimer's and Dementia
Volumen12
N.º2
DOI
EstadoPublished - feb 1 2016

Nota bibliográfica

Publisher Copyright:
© 2016 The Alzheimer's Association.

Financiación

This work was supported by the following grants from the National Institute on Aging , National Institutes of Health : the, National Alzheimer's Coordinating Center ( U01 AG016976 ), Alzheimer's Disease Centers ( P50 AG05133 , P50 AG05134 , P50 AG05136 , P50 AG05681 , P30 AG10161 , P30 AG10124 , P30 AG13854 , P50 AG16570 , P30 AG19610 , and P30 AG28383 ), and P01 AG03991 . We thank Dr Kathleen Montine for editorial assistance. This work was supported by the following grants from the National Institute on Aging, National Institutes of Health: the, National Alzheimer''s Coordinating Center (U01 AG016976), Alzheimer''s Disease Centers (P50 AG05133, P50 AG05134, P50 AG05136, P50 AG05681, P30 AG10161, P30 AG10124, P30 AG13854, P50 AG16570, P30 AG19610, and P30 AG28383), and P01 AG03991. We thank Dr Kathleen Montine for editorial assistance.

FinanciadoresNúmero del financiador
Alzheimer's Disease CentersP50 AG05133, P30 AG10124, P50 AG16570, P50 AG05134, P30 AG28383, P50 AG05136, P30 AG13854, P30 AG19610, P01 AG03991, P30 AG10161, P50 AG05681
National Alzheimer's Coordinating CenterU01 AG016976
National Institutes of Health (NIH)
National Institute on AgingP50AG005134, P01AG003991

    ODS de las Naciones Unidas

    Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

    1. Good health and well being
      Good health and well being

    ASJC Scopus subject areas

    • Epidemiology
    • Health Policy
    • Developmental Neuroscience
    • Clinical Neurology
    • Geriatrics and Gerontology
    • Cellular and Molecular Neuroscience
    • Psychiatry and Mental health

    Huella

    Profundice en los temas de investigación de 'Multisite assessment of NIA-AA guidelines for the neuropathologic evaluation of Alzheimer's disease'. En conjunto forman una huella única.

    Citar esto